Uptrend Under Pressure 100
Institutional selling is building — 7 distribution days in the last 25 sessions. Severe risk · 100/100 · 7 distribution days (SPY) Oct 26 Full briefing →
View
Simple research view

BIO · Bio-Rad Laboratories, Inc.

$372.43 +0.67% Oct 26 close
Detected setup watchlist_candidate · Setup Score 0/100

Stand aside — setup invalidated

Setup score 0, but distribution days reach 5 or more — stand aside until the condition resets.

1 independent risk warning also present. Review before relying on the bullish setup.

Ask about BIO

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

$BIO

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. is a large-cap Medical Specialties company in the Health Technology sector with a market cap of $10B.

Health Technology Medical Specialties stock Stage 2 · Advancing Base 2
$372.43 latest close
Market Structure
Trend structure: downtrend
Latest event: structure_shift (bearish)
Support 328.25–328.55 · 3 touches · moderate
Support 293.94–296.15 · 3 touches · moderate
Support 312.27–313.41 · 3 touches · moderate
Support 351.80–353.97 · 3 touches · moderate
Momentum Turn Watch
Daily Bullish RSI Divergence Price made a lower low ($355.57→$352.82) while RSI made a higher low (37→39). Treat it as early momentum evidence until price confirms a turn.
Bollinger Squeeze Bollinger band width (8.8%) is in the bottom quartile of its last 120 sessions — Legend's width-percentile squeeze (not a TTM/Keltner squeeze), so volatility is compressed and a sharper move often follows.
Early technical context only. Wait for price, volume, and the canonical setup trigger to confirm; this signal does not change readiness or the setup score.
Join to Watchlist $BIO Share card
Verdict · setup score 0/100 · data Oct 26 close · latest session

Stand aside — setup invalidated

Setup score 0, but distribution days reach 5 or more — stand aside until the condition resets.

Review six verdicts Inspect chart
Recent price action · daily
$350$400AugSepOct$372

What would change this verdict

What needs to turn for this to become buyable — the top failing checks across the legend council:

  • Minervini 1.5 Price > 50-day MA — Price $372.43 vs MA50 $373.32
  • Minervini 2. Quarterly EPS growth ≥ 25% — -24.7% QoQ
  • O'Neil C: Quarterly EPS acceleration ≥ 25% — -24.7% QoQ
  • O'Neil L: RS rank ≥ 80 (IBD leadership) — RS rank 79
  • Weinstein Volume expansion above average — Volume ratio 0.71x
  • Weinstein 30-week MA trending upward
Minority view — the council disagrees here
  • Minervini: avoid Trend-template read: fails Price > 50-day MA.
  • O'Neil: avoid CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.
  • Weinstein: watch Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.
61 Neutral
Legend Score · rates the stock Neutral (61/100) — held back by eps growth

Our proprietary 0-100 rating — the answer to Wall Street's black-box scores. Five pillars, each computed from real scan data, each explained below in plain English.

  • Relative Strength (25%) 80
  • Trend Template (25%) 88
  • Institutional Footprint (20%) 38
  • EPS Growth (15%) 30
  • Quality (SMR-like) (15%) 44

RS rank 79: above-average strength. Trend template 7/8: price above rising 50/150/200-day lines — textbook uptrend structure. Institutional score 38: mild distribution — sellers active. EPS -0% last quarter — no earnings momentum. Quality 44: weak fundamentals (sales growth 30, return on equity 40, leverage 100). Updated 2026-10-27.

Earnings

Pre-earnings setup

Next earnings Tuesday, October 27, 2026 After market close Exact clock time not supplied by source

Deterministic evidence

BIO+0.67%
Sector proxy · XLV+0.00%
Broad market · SPY+0.71%
Same completed session window ending 2026-10-26. BIO was +0.67 points vs XLV. -0.04 points vs SPY.
CatalystPending Stock reactionPositive Sector reactionWeak Opening surgePending Event riskEarnings-driven

Session internals Mixed

Rule: direction and internals disagree — it met neither the strong nor the weak rule. Judged on internals, not on the size of the move.

Vs prior close+0.67% From the open+0.17% Range position43% GapNo gap
QQQ confirmationConfirming (+1.11%) SMH confirmationConfirming (+2.74%)
Short-term conviction -1 points.
  • A sourced earnings report is still pending inside the risk window; ordinary technical conviction is reduced until it is out.
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.

Price $372.43 +0.7% Oct 26 close
52W High $396.23 6.0% below high
Wks Since High 8w
Base Depth 9.6% 12.4% today
RS Rank 56 percentile of scan
SMA 50 $373.32
Avg Vol 253,122
Rel Vol (Oct 26) 0.71× 1.00× on up days
More stats
52W Low $236.73
Tight Wks 0
Base B2
SMA 200 $312.23
RS Line vs High -4.5%
RS Line Slope -2.0% ▼
Group Rank #20/66
ADR% 3.4%
ATR(14) $11.18 (3.0%)
Vol Pace (live) N/A
A/D Days 20A / 13D
A/D Rating A+
VDU Bars 0/10 d
Earnings TODAY
Position in 52-week range 85thpercentile of the 52-week range
$236.73low
$396.23high

BIO Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for BIO.

Create Free Account

Technical Analysis Report Card

$BIO · $372.43 · as of 2026-10-26 · multi-factor read
67
/ 100
Technicals 67/100
Reference read from price & volume only — the verdict at the top of the page decides the action.

Trend · Daily / Weekly / Monthly

Daily ▬ Sideways / consolidating
Weekly ▬ Sideways / consolidating
Monthly ▬ Sideways / consolidating

Moving Averages

50-day$373.32 ↓
100-day$341.15 ↑
200-day$312.23 ↑
Bullish (50 > 200)

RSI (14)

Reading54.8 · Neutral

Neutral — momentum is balanced between buyers and sellers.

MACD (12/26/9)

StateImproving
Histogram+0.793

Improving — MACD crossed above its signal line but still below zero. Histogram expanding.

Bollinger Bands (20,2)

%B / Width72% · 8.8%
Squeeze — volatility compressing

Mid-band — no directional band edge in play. Bands are squeezing — volatility is compressing, often a precursor to a sharp move.

Volume · Buyer vs Seller

Up/Down vol1.0 · Neutral
Rel volume0.71×
Pocket pivots · 10d1
5d vs 50d vol91%
Heavy vol up / down0 / 0

Balanced — up/down volume is roughly even; no clear hand. Recent volume is easing versus its baseline.

  • Pocket pivot 3 sessions ago — up-day volume beat every down day of the prior 10 sessions.

Support & Resistance

R · $389.69swing level
R · $396.2352-week high
Price · $372.43now
S · $365.66swing level
S · $353.30swing level
S · $285.39swing level

Fibonacci · Uptrend swing

23.6%$358.59
38.2%$335.30
50.0%$316.48
61.8%$297.66
78.6%$270.86

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for BIO — plus the full 500+ symbol scanner and Ask-the-Legends chat.
Start your 7-day free trial →
Above 200-day MA50/200 bullish
Want this read in a legend's voice? Ask a Legend about BIO
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.
How to read the numbers: the setup score (0/100, in the verdict band) rates this trade setup. Each legend's A–D grade rates the same setup against that legend's own checklist — so a high score next to a C grade is not a contradiction. The setup can be strong without fitting that legend's style. When the council disagrees, the verdict band breaks the tie.

Council consensus: 6 of 9 legends are Watching — building, not yet a confirmed buy.
Minervini Avoid C Trend-template read: fails Price > 50-day MA.
Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $372.43, MA150 $320.75, MA200 $312.23
1.2 150-day MA > 200-day MAMA150 $320.75 vs MA200 $312.23
Failing evidence
1.5 Price > 50-day MAPrice $372.43 vs MA50 $373.32
2. Quarterly EPS growth ≥ 25%-24.7% QoQ
6/10 checks
Method → Playbook → Ask →
O'Neil Avoid D CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.
Passing evidence
N: Near 52-week high or RS line new high6.0% below high | RS line new high: False
S: Base tightness (ATR% ≤ 4.5%)ATR% 3.00%
Failing evidence
C: Quarterly EPS acceleration ≥ 25%-24.7% QoQ
L: RS rank ≥ 80 (IBD leadership)RS rank 79
2/8 checks
Method → Playbook → Ask →
Weinstein Watch C Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.

mediumClassic Stage 2 advancing phase — strong weekly trend confirms uptrend. This is Weinstein's sweet spot: buy and hold while price remains above the 30-week MA.

Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $372.43 vs MA200 $312.23
Failing evidence
Volume expansion above averageVolume ratio 0.71x
30-week MA trending upwardData unavailable
4/6 checks
Method → Playbook → Ask →
dennis Watch C Turtle read: no Donchian signal. The system stays flat until price takes out the 20-day high.
Passing evidence
No breakdown below the 20-day channel20-day low $347.29
Volatility-unit sizing (1N ≈ 1% of equity)1N = $11.44 (3.07% of price); the Turtles size 1 unit so a 1N move ≈ 1% of equity, making the 2N stop ≈ 2% equity risk
Failing evidence
S1: 20-day Donchian breakoutNot confirmed
S2: 55-day Donchian breakoutNot confirmed
5/7 checks
Method → Playbook → Ask →
zanger Avoid D Zanger read: a hard gate is broken — either the pattern is not one of his six, or the entry is more than 5% past the breakout. He would not touch this.
Passing evidence
Partial-profit plan: sell 20-30% at +15-20%Scale 20-30% at $428.29-$446.92; trail the rest
Trail on the 10/20-day MA10-day MA $361.84 · 20-day MA $365.39 — exit the remainder on a close below the trail
Failing evidence
Named Zanger pattern onlywatchlist_candidate is not one of Zanger's six
Not extended (≤5% above the breakout point)Data unavailable
3/6 checks
Method → Playbook → Ask →
zweig Watch D Zweig read: part of his screen passes but not all: EPS growth above the market (≥15% QoQ); Insider buying — wait for the full growth screen before treating this as a Zweig setup.
Passing evidence
Reasonable price for the growth (P/E ≤ 35)Trailing P/E 13.4x — no PEG or forward P/E stored
Price strength (RS ≥ 70)RS score 79 — Zweig buys strength, not bargains
Failing evidence
EPS growth above the market (≥15% QoQ)-24.7% QoQ — Zweig wants growth above the S&P average
Insider buyingNo insider buying flagged
4/8 checks
Method → Playbook → Ask →
Livermore Watch B Pivotal-point read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$372.43
Relative strengthRS 79
Failing evidence
Volume vs average0.71x
Pivotal point cleared on expanding volumeNot confirmed
4/6 checks
Method → Playbook → Ask →
Darvas Watch B Box-theory read: constructive evidence is present, but volume vs average is unresolved.

mediumBuilding the top of the box (6.0% from 52W high) — watch for a box breakout with volume expansion.

Passing evidence
Price$372.43
Relative strengthRS 79
Failing evidence
Volume vs average0.71x
Box top broken on heavy volumeNot confirmed
4/6 checks
Method → Playbook → Ask →
Wyckoff Watch B Supply-and-demand read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$372.43
Relative strengthRS 79
Failing evidence
Volume vs average0.71x
Sign of Strength confirmed on expanding volumePrice hasn't cleared the pivot yet — confirmation pending
4/6 checks
Method → Playbook → Ask →
Base & Breakout
Breakout follow-through

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

Unlock Base & Breakout Tracking
RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▼ Falling
99RS Line (52W)
Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net +2 A+
A: 15 D: 13 Net: +265 sessions
Minervini · Grade Card
Fundamentals & leadership quality — Minervini’s published criteria · 3/7 met
C 3/7 criteria
Separate score from the Minervini Trend Template (7/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
✗ EPS acceleration ≥25% QoQ -25%
✗ Revenue growth ≥20% YoY +1%
✓ Gross margin ≥30% 52%
✗ ROE ≥17% 2%
✗ RS rating ≥80 (leadership) 79
✓ Stage 2 uptrend (Weinstein) Stage 2
✓ Within 25% of 52W high -6.0%

Method Playbook

Trade it like Darvas EXACT LEVELS · PRO
Darvas B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro level
Published-method rule: Use the top of the active Darvas box near the high as the mechanical breakout boundary.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro level
Published-method rule: Require price to clear the box top with volume confirmation; movement inside the box remains observation, not a trigger.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro level
Published-method rule: Start below the active box support or the canonical structural stop that proves the breakout failed.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-based
Published-method rule: As higher boxes form, raise the stop beneath the newest confirmed box floor; the stop moves up only.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro level
Published-method rule: Exit when price breaks the active box floor or decisively falls back through the breakout structure.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →

Pattern Analysis

watchlist_candidate
0 setup score
RS Score 79
Trend template 7/8
Why This Setup?
The Universal Edge Check · context only

What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.

1/7 universals met
  • A relative-strength leader — not met RS rank 56 — laggard
  • Clear of earnings — not met in 0 days — event risk
  • Risk is defined — not met No stop — undefined risk
  • Asymmetric reward — partly met No target set
  • Not chasing (in range) — partly met Pivot distance unknown
  • Volume confirms — partly met 0.7× average — light
  • In a confirmed uptrend — met Stage 2 · Trend template 7/8
Why these seven? → The Universal Edge

Minervini Trend Template

7/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $372.43 vs SMA150 $320.75 / SMA200 $312.23
SMA 150 above SMA 200 SMA150 $320.75 vs SMA200 $312.23
SMA 200 trending up Slope +5.70 over 20 days
SMA 50 above SMA 150 & 200 SMA50 $373.32
Price above SMA 50 $372.43 vs SMA50 $373.32
30%+ above 52-week low +57.3% from $236.73
Within 25% of 52-week high -6.0% from $396.23
RS score above 70 RS 79

Fundamentals

52W Range
85%
Mkt Cap SEC
10.3B
EPS QoQ
-25%
Rev YoY
+1%
ROE
2%
Gross Margin
52%
D/E
0.16
EPS TTM
$27.85
P/E TTM
13.4x
Float
28M
Insider
No Buy

Company

Company profile
Bio-Rad Laboratories, Inc.
BIO · NYSE · Health Technology · Medical Specialties
Track all markets on TradingView

Scan History

2× streak
Oct 07: 86 (Pocket Pivot)Oct 06: 86 (Pocket Pivot)Oct 07: 79 (Trend Only)Oct 07: 80 (Trend Only)Oct 26: 55 (Pocket Pivot)Oct 27: 0 (watchlist_candidate)0
Oct 27
watchlist_candidate
0
Oct 26
Pocket Pivot
55 0.0%
Oct 07
Trend Only ✓ Gate
80 +1.2%
Oct 07
Trend Only ✓ Gate
79 +1.2%
Oct 06
Pocket Pivot ✓ Gate
86 +1.0%
Oct 07
Pocket Pivot ✓ Gate
86 +1.2%

Latest News

Headlines for BIO
Loading headlines…

Get the full picture on BIO

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.

Start 7-Day Free Trial